Nama Insights

Maravai LifeSciences (MRVI)

Healthcare · Biotechnology · NASDAQ

Maravai LifeSciences (MRVI) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $1.87B and a free-cash-flow yield of -6.8%. Over the most recent reported fiscal year, revenue declined 28.3%. Nama's AI scorecard rates it Sell, 3.3 out of 10. On 12-month momentum it ranks in the leading band of its market.
AI scorecard
Sell · 3.3/10
Negative, at the mild end of Sell. As of Nov 20, 2026.
Momentum
Leading · +121.3% over 12 months ex. last
Top 20% of its market on the past year's steady rise.
Shariah screen
Shariah Compliant
Passes our debt, cash and income screen; not a scholar's ruling.
Off its high
-84.9%
How far the last close sits under the highest price of the past five years.
Market cap$1.87B
Trailing P/E—
Price / book5.5
Price / sales8.8
FCF yield-6.8%
Dividend yield—
Gross margin39.1%
Operating margin-25.6%
Net margin-30.8%
Revenue growth (YoY)-28.3%
Revenue growth (3-yr annual)-40.5%
EPS growth (YoY)—
FCF/share growth (YoY)—
Beta0.6
ExchangeNASDAQ
SectorHealthcare
IndustryBiotechnology

MRVI earnings

Next report: Feb 24, 2027 (Q4 2026, EPS estimate -$0.04). Beat the EPS estimate in 4 of 4 recent quarters.

QuarterReportedEPSEstimateSurpriseRevenue
Q3 2026 Nov 4, 2026 -$0.03 -$0.06 +50.0% $45.85M
Q2 2026 Aug 6, 2026 -$0.02 -$0.04 +50.0% $51.44M
Q1 2026 May 7, 2026 $0.01 -$0.05 +120.0% $65.84M
Q4 2025 Feb 25, 2026 -$0.04 -$0.07 +42.9% $49.87M

MRVI analyst price target

Median target $9.50 from 7 analysts, ranging $8.00 – $12.00.

Biotechnology peers

TickerCompanyMarket capP/E
VRTX Vertex Pharmaceuticals $132.01B 27.4
REGN Regeneron Pharmaceuticals $95.52B 16.7
MRNA Moderna $80.65B —
ARGX argenx $59.24B 32.9
ONC BeOne Medicines $45.66B 50.8
RPRX Royalty Pharma $38.94B 12.8
RVMD Revolution Medicines $34.48B —
INSM Insmed $31.69B —
Explore live MRVI data on Nama Insights →

MRVI FAQ

Is MRVI a buy?
Nama's AI scorecard currently rates Maravai LifeSciences Sell (3.3 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does MRVI report earnings?
Maravai LifeSciences's next scheduled report is on Feb 24, 2027. Analysts expect EPS of -$0.04.
What is the MRVI price target?
The median analyst price target from 7 analysts is $9.50, with a range of $8.00 – $12.00.
Is MRVI Shariah compliant?
Nama's AAOIFI-style screen reads Maravai LifeSciences as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.